Pembrolizumab in paediatric patients with advanced melanoma or a PD-L1-positive, advanced, relapsed, or refractory solid tumour or lymphoma (KEYNOTE-051): interim analysis of an open-label, single-arm, phase 1–2 trialBirgit Geoerger, Navin Pinto, Hyoung Jin Kang et al.|The Lancet Oncology|2019Cited by 341
Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use programKai Hübel, Nicolaus Kröger, Rita Beier et al.|Bone Marrow Transplantation|2010Cited by 79